Pulmonary Arterial Hypertension Market to Expand at CAGR of 5.4% During Forecast Period, Says TMR Study

• Key companies and governments have launched many educational and awareness initiatives to spread information about PAH among healthcare professionals and patients, which is expected to boost the global market
• In the near future, the pulmonary arterial hypertension market is expected to be propelled by increase in life expectancy and geriatric populace in developing countries

ALBANY, N.Y., May 2, 2022 /PRNewswire/ -- The value of the global pulmonary arterial hypertension market stood at US$ 5.2 Bn in 2020. The global market is estimated to rise at a CAGR of 5.4% during the forecast period, from 2021 to 2028. It is anticipated to attain the valuation of US$ 13.5 Bn by 2028. PAH is an uncommon and progressive illness marked by high blood pressure in the pulmonary arteries. When the diameter of the pulmonary arteries narrows or becomes obstructed, PAH develops. The PAH problem has been more common in recent years as a result of escalating risk factors such as smoking, HIV, alcohol intake, sedentary lifestyles, cigarette, and various other idiopathic disorders. Due to the rising incidence of PAH throughout the world, market participants are likely to experience growth in the near future.

Request Brochure of Pulmonary Arterial Hypertension (PAH) Market Research Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1181 

There are a variety of medicines available in the market that can assist in managing and delaying the progression of illness, whilst enhancing quality of life. In addition, approval of some successful medications as well as presence of a promising pipeline are two major reasons likely to drive the global market. Favorable government regulations have helped to accentuate demand in the global pulmonary arterial hypertension market.

In order to gain advantage over competitors, firms in the global pulmonary arterial hypertension (PAH) market are accelerating product development and tapping revenue potential. Market participants are also expanding their service offerings to acquire a competitive advantage. Companies are concentrating on providing patients with effective yet affordable solutions.

Request for Analysis of COVID-19 Impact on Pulmonary Arterial Hypertension (PAH) Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1181 

Key Findings of Market Report

• The prostacyclin & prostacyclin analogs category is expected to dominate the global pulmonary arterial hypertension (PAH) market in terms of drug class. This is due to rising prevalence of PAH and growing demand for it.
• The global pulmonary arterial hypertension market is likely to be driven by increase in elderly population in developing countries in the near future. During the forecast period, the global market is projected to be driven by growing prevalence of PAH in the senior populace. One of the non-modifiable variables that raises the risk of PAH is ageing. Owing to diastolic dysfunction and age-related blood vessel stiffness, elderly people are more vulnerable to this condition.
• North America is expected to lead the global pulmonary arterial hypertension (PAH) market during the forecast period. North America is trailed by Europe, with both regional markets expected to develop significantly during the projected timeframe. This can be attributed to the availability of novel PAH medicines for commercialization, as well as a highly promising drug pipeline. Furthermore, better understanding about the increase in availability of medications for pulmonary arterial hypertension among individuals in both the regions is likely to fuel market expansion.

Get Exclusive PDF Sample Copy of Pulmonary Arterial Hypertension (PAH) Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181

Global Pulmonary Arterial Hypertension (PAH) Market: Growth Drivers

• The SGC simulators category is expected to rise at a high pace. By potentiating NO-sGC signaling, sGC stimulators can assure maximal sGC activation. The only medicine authorized for PAH in this category is Riociguat (Adempas from Bayer).
• Leading companies' growing focus on partnerships and mergers to develop novel solutions is expected to propel the global market in the years to come. Bayer AG and Vectura Group plc expanded their partnership in 2017 to devise advanced version of Breelib nebulizer that increases the effectiveness of iloprost aerosol treatment for pulmonary atrial hypertension.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1181 

Global Pulmonary Arterial Hypertension (PAH) Market: Key Competitors

• United Therapeutics Corp
• Actelion Pharmaceuticals Ltd.
• Novartis International AG
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Bayer HealthCare

Global Pulmonary Arterial Hypertension (PAH) Market: Segmentation

Pipeline Analysis

• Early-stage Drug Candidates
• Late-stage Drug Candidates

Drug Class

• Prostacyclin & Prostacyclin Analogs
• Endothelin Receptor Antagonists [ERAs]
• Phosphodiesterase-5 [PDE-5] Inhibitors
• Soluble Guanylate Cyclase [sGC] Stimulators

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Industry Research Reports by Transparency Market Research:

Gene Therapy Market: Gene therapy market was valued at US$ 1.3 Bn in 2020 and is projected to expand at a CAGR of 19.8% from 2017 to 2028. Gene therapy is a way of fixing genetic disorders by introducing a normal and healthy gene in place of the defective one in a cell to prevent or cure different types of genetic and chronic disorders for which no cure has been developed.

Geriatric Care Services Market: Geriatric care services market was valued at US$ 0.4 Bn in 2020. It is projected to expand at a CAGR of 5.3% from 2021 to 2028. The proportion of geriatric population among the total population continues to rise and is the single largest driver of the global geriatric care services market. Changing family structure in most developed countries has led to a decline in the time family caregivers can provide.

Bioinformatics Market: Bioinformatics market was valued at US$ 24.7 Bn in 2020 and is projected to expand at a CAGR of 5.9% from 2021 to 2028. Bioinformatics is used to manage the data gathered from research & development projects in the biopharmaceutical, life sciences, and biotechnology industries. Growth of the bioinformatics market is driven by rise in applications of IT in the healthcare sector, along with robust technological advancements.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Follow Us: Twitter | LinkedIn 
Blog: https://tmrblog.com 
Browse PR - https://www.transparencymarketresearch.com/pressrelease/pulmonary-arterial-hypertension-therapeutics.htm 

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg